

---

**SECURITIES AND EXCHANGE COMMISSION**  
WASHINGTON, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER**  
Pursuant to Rule 13a-16 or 15d-16 under  
the Securities Exchange Act of 1934

For the month of: January 2018

Commission File Number: 001-35776

---

**ACASTI PHARMA INC.**  
(Name of Registrant)

---

**545 Promende du Centropolis**  
**Suite 100**  
**Laval, Québec**  
**Canada H7T 0A3**  
(Address of Principal Executive Office)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): N/A

---

This Report on Form 6-K including the exhibits hereto shall be deemed to be incorporated by reference into Acasti Pharma Inc.'s registration statement on Form S-8 (File No. 333-191383) and to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**ACASTI PHARMA INC.**

Date: January 4, 2018

By: /s/ Jan D'Alvise

Name: Jan D'Alvise

Title: Chief Executive Officer

---

## EXHIBIT INDEX

<u>Exhibit</u>	<u>Description of Exhibit</u>
<a href="#">99.1</a>	<a href="#">Press release dated January 4, 2018</a>

---



### **Acasti Expands Global Patent Portfolio with Newly Granted Patents in South Korea and Canada**

**LAVAL, Québec, January 4, 2018 -- Acasti Pharma Inc.** (NASDAQ:ACST – TSX-V: ACST), an emerging biopharmaceutical company focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced the granting of a patent by the South Korean Patent Office and the granting of a corresponding patent by the Canadian Intellectual Property Office, further strengthening the international intellectual property position of CaPre.

The granted patents are valid until 2030 and relate to a concentrated phospholipid composition and method of using same for treating or preventing disorders associated with cardiovascular diseases. These patents add to Acasti's growing portfolio of issued patents in the United States, Taiwan, Australia, China, Japan, Mexico and Panama. Patent applications with similar claims are being pursued in several other jurisdictions.

"The granting of these additional patents further increase the global commercial opportunities for CaPre," highlighted Pierre Lemieux, Ph.D, Acasti's chief operating officer. "Both patents strengthen the competitive barriers for CaPre and provide market access to the Canadian and South Korean pharmaceutical territories, both of which have strong commercial potential for CaPre."

#### **About CaPre (omega-3 phospholipid)**

Acasti's prescription drug candidate, CaPre, is a highly purified omega-3 phospholipid concentrate derived from krill oil and is being developed to treat severe hypertriglyceridemia, a metabolic condition that contributes to increased risk of cardiovascular disease and pancreatitis. Its omega-3s, principally EPA and DHA, are either "free" or bound to phospholipids that help them to be better absorbed into the body. This allows for enhanced bioavailability and EPA and DHA blood levels compared to the "esterified" fish-oil omega-3 options such as LOVAZA.

#### **About Acasti Pharma**

Acasti Pharma is a biopharmaceutical innovator advancing a potentially best-in-class cardiovascular drug, CaPre® (omega-3 phospholipid), for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one third of the U.S. population. The corporation's strategy is to initially develop and commercialize CaPre for the 3 to 4 million patients in the U.S. with severe hypertriglyceridemia. Since its founding in 2008, Acasti Pharma has focused on addressing a critical market need for an effective, safe and well-absorbing omega-3 therapeutic that can make a positive impact on the major blood lipids associated with cardiovascular disease risk. For more information, visit [www.acastipharma.com](http://www.acastipharma.com).

---

## Forward Looking Statements

Statements in this press release that are not statements of historical or current fact constitute “forward-looking statements” within the meaning of the U.S. securities laws and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of Acasti to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement and the “Cautionary Note Regarding Forward-Looking Information” section contained in Acasti’s latest Annual Information Form, which also forms part of Acasti’s latest annual report on Form 20-F, and which is available on SEDAR at [www.sedar.com](http://www.sedar.com), on EDGAR at [www.sec.gov/edgar.shtml](http://www.sec.gov/edgar.shtml) and on the investor section of Acasti’s website at [acastipharma.com](http://acastipharma.com) (the “AIF”). All forward-looking statements in this press release are made as of the date of this press release. Acasti does not undertake to update any such forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in Acasti’s public securities filings with the Securities and Exchange Commission and the Canadian securities commissions. Additional information about these assumptions and risks and uncertainties is contained in the AIF under “Risk Factors.” Neither NASDAQ, the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.

SOURCE: Acasti Pharma Inc

###

### **Acasti Contact:**

Jan D’Alvise  
Chief Executive Officer  
450-686-4555  
[info@acastipharma.com](mailto:info@acastipharma.com)  
[www.acastipharma.com](http://www.acastipharma.com)

### **Media Contact:**

Jessica Dyas  
Canale Communications  
619-849-5385  
[jessica@canalecomm.com](mailto:jessica@canalecomm.com)

### **Investor Relations Contact:**

Glen Akselrod  
Bristol Capital Ltd.  
(905) 326-1888 ext 10  
[glen@bristolir.com](mailto:glen@bristolir.com)